The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Alimera Sciences sales in the US from 2017 to 2023, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Smarter leaders trust GlobalData
Alimera Sciences Inc (Alimera) focuses on the development and commercialization of prescription ophthalmic retinal pharmaceuticals. The company’s products are Iluvien and Yutiq, both of which are fluocinolone acetonide intravitreal implants used for the treatment of diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye. Iluvien is prescribed for the treatment of recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS); proliferative diabetic retinopathy (NPDR); wet and dry age-related macular degeneration (AMD) and retinal vein occlusion. Yutiq is prescribed for the treatment of chronic NIU-PS. The company distributes its products in France, Austria, Portugal, the Czech Republic, Denmark, Finland, Germany, Spain, the UK, and others. Alimera is headquartered in Alpharetta, Georgia, the US. Key subsidiaries of Alimera Sciences include Alimera Sciences Europe, Alimera Sciences Ophthalmologie, Alimera Sciences France, Alimera Sciences Opthamologie and Alimera Sciences (DE).
The key metrics of Alimera Sciences related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2023 are shown below:
As Alimera Sciences is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Alimera Sciences.
For a detailed understanding of the performance of Alimera Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.
